Company: Bentley Pharmaceutical
Starting stock price: $10.18
Ending stock price: $15.09
Percent Change: 48.23%
Details: Bentley Pharmaceutical has taken a two-pronged approach to the drug business. Its emerging drug delivery business focuses on commercializing products in the U.S., and its generics unit targets the European Union. Itâ€™s the seventh largest generics company in spain with a growing portfolio of drugs for cardio, gastrointestinal, infectious disease, and central nervous system uses. In October, the company announced that it would split these two businesses and consider â€œstrategic alternativesâ€ for the generics portion.
In the U.S., Bentley is working on a delivery technology that allows drugs to permeate membranes; it can be used in patches, gels, ointments, creams and emulsions. The company also has been developing an intranasal insulin product. It filed an SEC registration statement near yearâ€™s end to spin off this portion of the business into an independent company.